Top-Rated StocksTop-RatedNASDAQ:SRPT Sarepta Therapeutics (SRPT) Stock Price, News & Analysis $127.93 +2.92 (+2.34%) (As of 12:31 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Sarepta Therapeutics Stock (NASDAQ:SRPT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$125.78▼$128.6550-Day Range$124.33▼$152.6752-Week Range$55.25▼$173.25Volume197,072 shsAverage Volume1.30 million shsMarket Capitalization$12.09 billionP/E Ratio1,163.00Dividend YieldN/APrice Target$187.39Consensus RatingModerate Buy Company OverviewSarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.Read More… Biden's Executive Order, Dems Digital Money Legislation, First Step To (Ad)Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.This means you must act NOW before it's too late. Sarepta Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 98th PercentileSarepta Therapeutics scored higher than 98% of companies evaluated by MarketBeat, and ranked 21st out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingSarepta Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.95, and is based on 16 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageSarepta Therapeutics has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sarepta Therapeutics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth603.40% Earnings GrowthEarnings for Sarepta Therapeutics are expected to grow by 603.40% in the coming year, from $1.47 to $10.34 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sarepta Therapeutics is 1,144.45, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 139.51.Price to Earnings Ratio vs. SectorThe P/E ratio of Sarepta Therapeutics is 1,144.45, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 147.31.Price to Book Value per Share RatioSarepta Therapeutics has a P/B Ratio of 13.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Sarepta Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.91% of the outstanding shares of Sarepta Therapeutics have been sold short.Short Interest Ratio / Days to CoverSarepta Therapeutics has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Sarepta Therapeutics has recently decreased by 2.97%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSarepta Therapeutics does not currently pay a dividend.Dividend GrowthSarepta Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.65 Percentage of Shares Shorted6.91% of the outstanding shares of Sarepta Therapeutics have been sold short.Short Interest Ratio / Days to CoverSarepta Therapeutics has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Sarepta Therapeutics has recently decreased by 2.97%, indicating that investor sentiment is improving. News and Social Media2.7 / 5News Sentiment0.93 News SentimentSarepta Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Sarepta Therapeutics this week, compared to 10 articles on an average week.Search InterestOnly 14 people have searched for SRPT on MarketBeat in the last 30 days. This is a decrease of -26% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Sarepta Therapeutics insiders have sold 69.49% more of their company's stock than they have bought. Specifically, they have bought $4,955,684.00 in company stock and sold $8,399,586.00 in company stock.Percentage Held by InsidersOnly 7.70% of the stock of Sarepta Therapeutics is held by insiders.Percentage Held by Institutions86.68% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sarepta Therapeutics' insider trading history. SRPT Stock News HeadlinesInsider Selling: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) CFO Sells 5,985 Shares of StockSeptember 4, 2024 | insidertrades.comInsider Buying: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Acquires 37,038 Shares of StockAugust 21, 2024 | insidertrades.comBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.September 19, 2024 | Monetary Gold (Ad)This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?Avidity Biosciences' stock has performed incredibly well in 2024. Its Duchenne muscular dystrophy drug is showing strong results in trials.August 19, 2024 | marketbeat.comImplied Volatility Surging for Sarepta Therapeutics (SRPT) Stock OptionsSeptember 19 at 12:52 PM | msn.comSarepta Therapeutics (SRPT) Receives a Buy from RBC CapitalSeptember 19 at 12:52 PM | markets.businessinsider.comUBS Group Increases Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $188.00September 19 at 3:34 AM | americanbankingnews.comSarepta Therapeutics Muscles Up In DMD RaceSeptember 18 at 11:59 PM | seekingalpha.comSee More Headlines SRPT Stock Analysis - Frequently Asked Questions How have SRPT shares performed this year? Sarepta Therapeutics' stock was trading at $96.43 at the beginning of 2024. Since then, SRPT shares have increased by 30.6% and is now trading at $125.89. View the best growth stocks for 2024 here. How were Sarepta Therapeutics' earnings last quarter? Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced its quarterly earnings results on Wednesday, August, 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.01 by $0.06. The business's revenue was up 38.9% compared to the same quarter last year. Does Sarepta Therapeutics have any subsidiaries? Sarepta Therapeutics subsidiaries include these companies: Myonexus Therapeutics, Eisai, Sarepta Securities Corp., Sarepta Therapeutics Three LLC, and ST International Holdings Two Inc.. Who are Sarepta Therapeutics' major shareholders? Sarepta Therapeutics' top institutional investors include Avoro Capital Advisors LLC (3.17%), Susquehanna International Group LLP, Thrivent Financial for Lutherans (0.68%) and Federated Hermes Inc. (0.54%). Insiders that own company stock include Douglas S Ingram, Michael Andrew Chambers, Richard Barry, Ian Michael Estepan, Hans Lennart Rudolf Wigzell, Bilal Arif, Dallan Murray, Ryan Edward Brown, Kathryn Jean Boor, Stephen Mayo and Louise Rodino-Klapac. View institutional ownership trends. How do I buy shares of Sarepta Therapeutics? Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Sarepta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA) and Netflix (NFLX). Company Calendar Last Earnings8/07/2024Today9/19/2024Next Earnings (Estimated)11/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SRPT Previous SymbolNASDAQ:AVII CUSIPN/A CIK873303 Webwww.sareptatherapeutics.com Phone(617) 274-4000Fax425-354-5038Employees1,314Year Founded1980Price Target and Rating Average Stock Price Target$187.39 High Stock Price Target$235.00 Low Stock Price Target$109.00 Potential Upside/Downside+45.9%Consensus RatingModerate Buy Rating Score (0-4)2.95 Research Coverage19 Analysts Profitability EPS (Most Recent Fiscal Year)$0.11 Trailing P/E Ratio1,167.27 Forward P/E Ratio87.35 P/E GrowthN/ANet Income$-535,980,000.00 Net Margins3.14% Pretax Margin4.13% Return on Equity5.32% Return on Assets1.50% Debt Debt-to-Equity Ratio1.05 Current Ratio3.90 Quick Ratio3.19 Sales & Book Value Annual Sales$1.50 billion Price / Sales8.06 Cash FlowN/A Price / Cash FlowN/A Book Value$9.19 per share Price / Book13.97Miscellaneous Outstanding Shares94,524,000Free Float87,246,000Market Cap$12.14 billion OptionableOptionable Beta0.81 Social Links This page (NASDAQ:SRPT) was last updated on 9/19/2024 by MarketBeat.com Staff From Our PartnersChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredTrump Warns Gov. Can Confiscate Your Money. CBDC's give Gov. absoluteDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredWall St. Icon: Looming Financial Tsunami will Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event will hit the American...InvestorPlace | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredKamala Harris To Tank the Market?URGENT ELECTION MELTDOWN WARNING From the former CIA advisor who predicted President Trump’s win in 2016…Paradigm Press | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Sarepta Therapeutics, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.